Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0140-6736(73)92470-7 | DOI Listing |
J Cancer Res Ther
December 2024
Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, P.R. China.
Background: Cryoablation induces antitumor immune responses. Spatial transcriptomic landscape technology has been used to determine the micron-level panoramic transcriptomics of tissue slices in situ.
Methods: The effects of cryoablation on the immune microenvironment in non-small cell lung cancer (NSCLC) were explored by comparing the Whole Transcriptome Atlas (WTA) panel of immune cells before and after cryoablation using the spatial transcriptomic landscape.
Cancers (Basel)
August 2023
Heat Pipe and Thermal Management Research Group, College of Engineering, Design and Physical Sciences, Brunel University, London UB8 3PH, UK.
Breast cancer is the most commonly diagnosed type of cancer, accounting for approximately one in eight cancer diagnoses worldwide. In 2020, there were approximately 2.3 million new cases of breast cancer globally, resulting in around 685,000 deaths.
View Article and Find Full Text PDFJ Vasc Interv Radiol
July 2023
Department of Radiology, University of California San Diego, La Jolla, California; VA San Diego Healthcare System, San Diego, California. Electronic address:
Mater Horiz
May 2023
Oncology Department, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, China.
Cancer vaccines developed from autologous tumors hold tremendous promise for individualized cancer immunotherapy. Cryoablation-induced autologous antigens are capable of activating systemic immunity with low damage. However, the dissipation of cancer fragments after cryoablation induces poor immunogenicity and short-time maintenance of immunological memory.
View Article and Find Full Text PDFClin Breast Cancer
June 2023
Breast Center, Kameda Medical Center, Kamogawa, Chiba, Japan.
Introduction: This is a prospective single arm clinical trial on cryosurgery for early breast cancers, to evaluate the expanded criteria to tumors larger than 1.5 cm and non-luminal breast cancers.
Methods: Inclusion criteria include Solitary T1 breast cancers of any immunohistotypes.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!